SAN DIEGO, Aug. 06, 2020 (GLOBE NEWSWIRE) -- Progenity, Inc. (NASDAQ: PROG), a biotechnology company with an established track record of success in developing and commercializing molecular testing products, today announced that it will report second quarter 2020 financial results on Thursday,

The Company has established and continues to make significant investments in industry-leading compliance protocols and reporting standards SAN DIEGO, July 23, 2020 (GLOBE NEWSWIRE) -- Progenity , Inc. (Nasdaq: PROG), a biotechnology company focused on providing complex molecular and specialized

SAN DIEGO, June 19, 2020 (GLOBE NEWSWIRE) -- Progenity, Inc . (NASDAQ: PROG), a biotechnology company with an established track record of success in developing and commercializing molecular testing products, today announced the pricing of its initial public offering of 6,666,667 shares of common

The four posters were released for the 2020 American College of Medical Genetics and Genomics’ (ACMG) Annual Clinical Genetics Meeting. SAN DIEGO, May 27, 2020— Progenity, a biotechnology company with an established track record of success in developing and commercializing molecular testing

Mr. Silvestry will be focused on delivering operational excellence, achieving ambitious growth targets, and driving the company’s service culture. SAN DIEGO, May 26, 2020— Progenity, a biotechnology company with an established track record of success in developing and commercializing molecular

Mr. Seelye will help to strengthen our technology and data strategy, leading the development of key products and services designed to transform the customer experience. SAN DIEGO, March 30, 2020— Progenity, a biotechnology company with an established track record of success in developing and

Our lab is fully operational and we are offering assisted patient education and collection services to support healthcare providers and patients. Recent public health measures related to the novel coronavirus are greatly impacting healthcare practices.

We will present results from clinical laboratory experience that indicate noninvasive prenatal testing (NIPT) performs well for predicting aneuploidies in twin pregnancies. SAN DIEGO – February 5, 2020  – Progenity, developing precision medicine solutions across genomic/epigenomic, proteomic, and

Highlighting our work to improve the diagnosis and management of patients with small intestinal bacterial overgrowth (SIBO). Progenity was featured in  Gastroenterology & Endoscopy News  for our work on a capsule that improves the diagnosis and management of patients with small intestinal bacterial

SAN DIEGO and DANVILLE, Pa.  – December 10, 2019 – Progenity, a privately held biotechnology company, and  Geisinger , one of the nation’s most innovative health services organizations, announced publication of a study in  Obstetrics & Gynecology  demonstrating the significant economic burden